Vertex Pharmaceuticals Inc

VRTX remains in a Stage 2 uptrend, consolidating just below its fresh highs with price above rising EMAs. The recent pullback into the 9- and 20-day EMA zone offers a favorable entry under the Stable strategy, so we engage now on pullback support for continuation toward new highs.

• ↑Q2 revenue $3.3B (+12% YoY), CF and new launches drive growth
• ↑Eliftrek surpasses $1B cumulative CF revenue with strong patient uptake
• ↓Uncertain approval timelines for POVI could delay renal revenues